DiaPep277 Granted Orphan Drug Designation by FDA

The U.S. FDA has granted Orphan Drug designation for DiaPep277 for the treatment of type 1 diabetes (T1D) patients with residual beta cell function. The designation of Orphan Drug status offers 7 years marketing exclusivity from the time of approval…. Read more

Positive Results for DiaPep277 Type 1 Diabetes Treatment in Phase 3 Study

Andromeda Biotech has announced positive initial results from a pivotal phase III clinical study of type 1 diabetes treatment, DiaPep227.
The 24-month randomized, placebo-controlled study was designed to assess the safety and efficacy of DiaPep277, a novel immunotherapeutic agent for the treatment of newly diagnosed patients with type 1 diabetes… Read more

Diapep277 and Me

When I was first diagnosed with type 1 diabetes, I was asked to participate in a clinical study for a diabetes “vaccine” called Diapep277.  I didn’t know anything about it (nor did I know anything about diabetes).  At the time, … Read more

Subscribe to our Newsletter

Hide me